Damora Therapeutics (DMRA) investor relations material

Strategic vision and leadership

• Focused on redefining care for blood disorders, particularly myeloproliferative neoplasms (MPNs) driven by CALR mutations.

• Founded by Fairmount Funds Management, with experienced R&D and commercial leadership.

• Supported by premier investors and $533 million in cash as of March 31, 2026.

Product pipeline and innovation

• Lead asset DMR-001 is a next-generation anti-mutCALR antibody with superior potency and optimized exposure for both Type 1 and Type 2 CALR mutations.

• DMR-001 designed for convenient, infrequent subcutaneous dosing via autoinjector, targeting chronic use.

• Additional assets include DMR-002 (Fc-enhanced) and DMR-003 (T-cell engager), with regulatory submissions planned for 2H 2026 and 2027, respectively.

• DMR-001 demonstrates 3x potency on Type 1 and 10x on Type 2 CALR mutations compared to reference mAb.

Market opportunity and unmet need

• MPNs such as essential thrombocythemia (ET) and myelofibrosis (MF) are debilitating, with current therapies failing to address the underlying disease.

• Estimated >$5B total addressable market in the US for mutCALR-driven MPNs, with ~42,000 patients.

• Significant initial opportunity in intermediate/high-risk populations, with expansion potential into lower-risk groups.

• Current standard of care leaves 20–30% of patients resistant or intolerant, highlighting need for targeted, disease-modifying therapies.